Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
K-111
Cat. No.:
0225LY-0824
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
K-111 is an orally available insulin enhancer and PPAR-alpha agonist used in the study of metabolic syndrome and obesity-related diabetes.
Synonym:
BM 170744; K111;K 111; BM170744; BM-170744; 221564-97-2; 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid; BM-17.0744; K-111; K111 (pharmaceutical); TM9XQR923G; UNII-TM9XQR923G; BM170744; Alpha,alpha,4-Trichlorobenzenedodecanoic acid; K-111-; Benzenedodecanoic acid, alpha,alpha,4-trichloro-; 2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid
CAS No.:
221564-97-2
Compound CID:
9929731
Formula:
C18H25Cl3O2
Formula Weight:
379.75
Specification
Relative Density:
1.199 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
K-111 can be used in metabolic pharmacology to investigate the potential of PPAR alpha agonism in treating dyslipidemia.
Library Information
Target:
PPAR
Receptor:
PPARα
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-11
Plate Location:
f3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
